Combination pembrolizumab plus chemotherapy: a new standard of care for patients with advanced non-small-cell lung cancer [0.03%]
派姆单抗联合化疗成为晚期非小细胞肺癌患者的新标准治疗方案
Frank Weinberg,Shirish Gadgeel
Frank Weinberg
Until recently, the treatment of patients with advanced non-small-cell lung cancer (NSCLC) whose tumors did not have a targetable genetic alteration was cytotoxic chemotherapy alone. This treatment provided only modest survival benefit. The...
Amifostine- and chemoradiotherapy-related esophagitis in small cell lung cancer: a single institutional series and literature update [0.03%]
氨磷汀和放化疗所致的小细胞肺癌食管炎：单中心系列研究及文献更新
Ariel E Pollock,Lowell Shinn,Richard Anderson et al.
Ariel E Pollock et al.
Objectives: Concurrent chemoradiotherapy is considered a standard option for patients with stage 3 small cell lung carcinoma. A 25% risk of acute esophagitis is experienced by patients as a result of the volume of esophag...
nab-paclitaxel/carboplatin induction in squamous NSCLC: longitudinal quality of life while on chemotherapy [0.03%]
纳妥铂紫杉醇/卡铂诱导治疗鳞状非小细胞肺癌：化疗期间纵向生活质量分析
Michael Thomas,David R Spigel,Robert M Jotte et al.
Michael Thomas et al.
Background: Longitudinal data on the impact of treatment on quality of life (QoL) in advanced non-small cell lung cancer (NSCLC) are limited. In this palliative setting, treatment that does not deteriorate QoL is key. Her...
Comparative effectiveness and safety of nab-paclitaxel plus carboplatin vs gemcitabine plus carboplatin in first-line treatment of advanced squamous cell non-small cell lung cancer in a US community oncology setting [0.03%]
纳武利尤单抗联合化疗对比吉西他滨联合化疗用于晚期肺鳞癌一线治疗的有效性和安全性：美国社区肿瘤机构的资料分析
Raja Mudad,Manish B Patel,Sandra Margunato-Debay et al.
Raja Mudad et al.
Introduction: Real-world comparative effectiveness, safety, and supportive care use of nab-paclitaxel plus carboplatin vs gemcitabine plus platinum were analyzed in patients with advanced or metastatic squamous cell non-s...
Trajectory of chemotherapy for patients with EGFR wild-type advanced pulmonary adenocarcinoma: a single-institution retrospective study [0.03%]
表皮生长因子受体阴性晚期肺腺癌化疗历程的单中心回顾性研究
Seigo Minami,Yoshitaka Ogata,Shouichi Ihara et al.
Seigo Minami et al.
Background: Pulmonary adenocarcinoma, recently benefited by new cytotoxic and molecularly targeted drugs, has been classified by driver mutations, such as EGFR mutations. The aim of this study was to research the proporti...
Outcomes and prognostic factors of chemotherapy for patients with locally advanced or metastatic pulmonary squamous cell carcinoma [0.03%]
晚期肺鳞癌化疗的疗效及预后因素分析
Seigo Minami,Yoshitaka Ogata,Shouichi Ihara et al.
Seigo Minami et al.
Background: Pulmonary squamous cell carcinoma has not benefited from improvements in chemotherapy over the past decade, compared with non-squamous non-small-cell lung cancer. Nowadays, treatment strategies differ between ...
Retrospective analysis of outcomes and prognostic factors of chemotherapy for small-cell lung cancer [0.03%]
小细胞肺癌化疗疗效的回顾性分析及预后因素研究
Seigo Minami,Yoshitaka Ogata,Shouichi Ihara et al.
Seigo Minami et al.
Background: Small-cell lung cancer (SCLC) is responsive to initial chemotherapy but becomes resistant to cytotoxic drugs. The aim of this study was to evaluate what proportion of patients with SCLC had received the first-...
Combination chemotherapy of gemcitabine and vinorelbine for pretreated non-small-cell lung cancer: a retrospective study [0.03%]
吉西他滨联合长春瑞滨治疗晚期非小细胞肺癌的回顾性分析
Seigo Minami,Yoshitaka Ogata,Suguru Yamamoto et al.
Seigo Minami et al.
Background: Advanced non-small-cell lung cancer (NSCLC) eventually progresses after first-line chemotherapy, and usually requires salvage treatment. Although neither gemcitabine nor vinorelbine is approved as a candidate ...
Hapten-enhanced therapeutic effect in advanced stages of lung cancer by ultra-minimum incision personalized intratumoral chemoimmunotherapy therapy [0.03%]
超微创精准瘤内化疗免疫治疗晚期肺癌的半抗原增强效应
Baofa Yu,Yuanfei Lu,Feng Gao et al.
Baofa Yu et al.
Aim: The objective of the study reported here was to evaluate the therapeutic effects of hapten-enhanced chemoimmunotherapy in the treatment of advanced lung cancer by ultra-minimum incision personalized intratumoral chem...
Gefitinib frequently induces liver damage in patients with lung adenocarcinoma previously treated by chemotherapy [0.03%]
吉非替尼可致既往接受过化疗的肺腺癌患者频繁发生肝损害
Yasoo Sugiura,Etsuo Nemoto,Osamu Kawai et al.
Yasoo Sugiura et al.
Background: Gefitinib is known as one of the agents for treating patients with both advanced lung cancer and an epidermal growth-factor receptor mutation. In the epidermal growth-factor receptor-mutant advanced non-small-...